TVTX
Travere Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$52.42
+6.09%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 651.0M | 490.7M | 233.2M | 145.2M | 109.5M |
| Cost of Revenue | 34.4M | 10.3M | 7.7M | 11.4M | 4.4M |
| Gross Profit | 616.7M | 480.4M | 225.4M | 133.8M | 105.0M |
| Operating Expenses | |||||
| R&D Expense | 245.6M | 206.0M | 282.7M | 245.0M | 227.3M |
| SG&A Expense | 376.5M | 337.2M | 264.1M | 265.5M | 197.5M |
| General & Admin Expense | 200.1M | 337.2M | 264.1M | 265.5M | 197.5M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 128.1M | — | 2.4M | 11.4M | — |
| Total Operating Expenses | 750.2M | 543.2M | 549.3M | 521.9M | 424.9M |
| Cost and Expenses | 784.5M | 553.6M | 557.0M | 533.4M | 429.3M |
| Operating Income (EBIT) | (133.5M) | (62.8M) | (323.8M) | (388.1M) | (319.8M) |
| Non-Operating | |||||
| Interest Income | 12.2M | 12.7M | 17.8M | 21.8M | 6.3M |
| Interest Expense | 8.9M | 10.7M | 11.2M | 11.3M | 11.0M |
| Net Interest Income | 3.4M | 2.0M | 6.6M | 10.4M | (4.7M) |
| Other Non-Op Income/Expense | (26.2M) | 13.6M | 3.3M | 12.0M | (11.3M) |
| Non-Operating Income (excl Interest) | 17.4M | (24.3M) | (14.5M) | (23.4M) | 328.0K |
| EBT (Pre-Tax Income) | (159.7M) | (49.3M) | (320.5M) | (376.1M) | (331.2M) |
| Income Tax Expense | (5.3M) | 988.0K | 120.0K | 223.0K | 313.0K |
| Bottom Line | |||||
| Net Income | (121.5M) | (25.5M) | (321.5M) | (111.4M) | (278.5M) |
| Earnings from Cont. Ops | (154.4M) | (50.3M) | (320.6M) | (376.3M) | (331.5M) |
| Earnings from Discont. Ops | 32.9M | 24.7M | (915.0K) | 264.9M | 53.0M |
| Bottom Line Net Income | (146.2M) | (50.3M) | (321.5M) | (111.4M) | (278.5M) |
| Per Share | |||||
| Basic EPS | ($1.56) | ($0.56) | ($4.08) | ($1.50) | ($4.37) |
| Diluted EPS | ($1.56) | ($0.56) | ($4.08) | ($1.50) | ($4.37) |
| Revenue Per Share | $6.88 | $5.50 | $2.96 | $1.96 | $1.72 |
| Shares | |||||
| Basic Shares Outstanding | 94.6M | 89.2M | 78.9M | 74.3M | 63.8M |
| Diluted Shares Outstanding | 94.6M | 89.2M | 78.9M | 74.3M | 63.8M |
| Profitability Metrics | |||||
| EBITDA | (98.1M) | 22.2M | (265.8M) | (326.2M) | (299.4M) |
| D&A | 52.8M | 60.7M | 43.6M | 38.5M | 20.7M |
| EBIT | (150.8M) | (38.5M) | (309.3M) | (364.8M) | (320.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2026